1. Scrip
  2. >>Business

CSL Makes $11.7bn Move On Vifor Pharma In Renal Disease Push

 
• By Alexandra Shimmings

Confirming rumors of an acquisition, CSL will venture into some new territories as well as boost its renal franchise when it takes over Switzerland’s Vifor Pharma in a deal worth $11.7bn.    

Kidney
• Source: Shutterstock

The Australian biotech leader CSL Limited is to buy Vifor Pharma Group  to beef up its renal presence and move into some adjacent therapeutic areas which, it believes, have high growth potential. The Swiss firm has recently been on an M&A spree itself, bringing more to the table for CSL in the form of Sanifit Therapeutics S.A. and Inositec AG.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble

 
• By Alaric DeArment

The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.